Interleukin 6 News and Research

RSS
Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.
Immunobridging study shows immunogenicity in adolescents receiving SARS-CoV-2 mRNA and inactivated vaccines

Immunobridging study shows immunogenicity in adolescents receiving SARS-CoV-2 mRNA and inactivated vaccines

The impact of PLEX on the survival of patients with severe COVID-19 and the effect on the cytokine release syndrome

The impact of PLEX on the survival of patients with severe COVID-19 and the effect on the cytokine release syndrome

Mice study shows how to improve long-term effectiveness of TB vaccine

Mice study shows how to improve long-term effectiveness of TB vaccine

Novel genetic relationships with severe SARS-CoV-2

Novel genetic relationships with severe SARS-CoV-2

Study reveals differential blood glycoprotein profiles in symptomatic and asymptomatic COVID-19 patients

Study reveals differential blood glycoprotein profiles in symptomatic and asymptomatic COVID-19 patients

Elevated P2X7 receptor levels in COVID-19 patients correlate with disease severity

Elevated P2X7 receptor levels in COVID-19 patients correlate with disease severity

Biomedical characterization of quantitative proteomics in a hospitalized cohort of COVID-19 patients

Biomedical characterization of quantitative proteomics in a hospitalized cohort of COVID-19 patients

Severity-dependent immune mechanisms in the cerebrospinal fluid and plasma of COVID-19 patients

Severity-dependent immune mechanisms in the cerebrospinal fluid and plasma of COVID-19 patients

Study explores COVID-19 vaccine effectiveness in ankylosing spondylitis patients

Study explores COVID-19 vaccine effectiveness in ankylosing spondylitis patients

Diabetes and the mTOR pathway in COVID-19 patients

Diabetes and the mTOR pathway in COVID-19 patients

Combating COVID cytokine storm with targeted nucleic acid therapies

Combating COVID cytokine storm with targeted nucleic acid therapies

CD4 T-cell immunity active six months into COVID-19 convalescence

CD4 T-cell immunity active six months into COVID-19 convalescence

Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

Pilot study opens the door to a promising new therapeutic alternative for PTSD patients

Pilot study opens the door to a promising new therapeutic alternative for PTSD patients

Study identifies unique features of MIS-C and how the syndrome gets started in children

Study identifies unique features of MIS-C and how the syndrome gets started in children

Using oral blood pressure drug to treat Type 1 diabetes shows benefits for at least two years

Using oral blood pressure drug to treat Type 1 diabetes shows benefits for at least two years

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

Dual therapeutic potential of zapnometinib against COVID-19

Dual therapeutic potential of zapnometinib against COVID-19

Adenosine receptor agonists provide therapeutic target in mouse SARS-CoV-2 infection

Adenosine receptor agonists provide therapeutic target in mouse SARS-CoV-2 infection

Analyzing transcriptomic landscape of SARS-CoV-2-infected lung cells

Analyzing transcriptomic landscape of SARS-CoV-2-infected lung cells

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.